将ζ缺陷型CAR整合入CD3ζ基因在T细胞和NK细胞中赋予强效细胞毒性
该研究提出利用CRISPR-Cas基因编辑将缺乏主要激活域的截短CAR转基因导入人CD3ζ(CD247)基因,生成功能性的CAR融合基因,利用内源性CD3ζ作为CAR的激活域。该方法实现了CAR表达的生理性调控,并可重定向多种免疫细胞类型,包括常规T细胞、TCRγ/δ T细胞、调节性T细胞和NK细胞。在T细胞中,CD3ζ框内融合消除了TCR表面表达,降低了异体通用型设置中移植物抗宿主病的风险。CD3ζ-CD19-CAR-T细胞在体内表现出与TRAC替换和慢病毒转导的CAR-T细胞相当的 leukemia 控制效果。调节CD3ζ-CAR表达水平显著改善了体内疗效。值得注意的是,CD3ζ基因编辑能够重定向NK细胞而不损害其经典功能。因此,CD3ζ基因编辑是开发使用重定向杀伤淋巴细胞的异体通用型细胞疗法的一个有前景的平台。
要点
- CRISPR-Cas将截短CAR转基因导入CD3ζ基因,利用内源性CD3ζ作为激活域。
- CD3ζ框内融合消除TCR表面表达,降低异体通用型GVHD风险。
- CD3ζ-CD19-CAR-T细胞体内白血病控制与TRAC替换及慢病毒转导相当。
核心结论
- CD3ζ基因编辑是开发使用重定向杀伤淋巴细胞的异体通用型细胞疗法的一个有前景的平台。
研究设计与样本
- 临床前研究,利用CRISPR-Cas基因编辑将缺乏主要激活域的截短CAR转基因导入人CD3ζ(CD247)基因,重定向T细胞和自然杀伤(NK)细胞。
主要发现
- CD3ζ框内融合在T细胞中消除了TCR表面表达,降低了异体通用型设置中移植物抗宿主病的风险。
- CD3ζ-CD19-CAR-T细胞在体内表现出与TCRα链恒定区(TRAC)替换和慢病毒转导的CAR-T细胞相当的白血病控制效果。
- 调节CD3ζ-CAR表达水平显著改善了体内疗效。
- CD3ζ基因编辑能够重定向NK细胞而不损害其经典功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR)-redirected immune cells hold significant therapeutic potential for oncology, autoimmune diseases, transplant medicine, and infections. All approved CAR-T therapies rely on personalized manufacturing using undirected viral gene transfer, which results in nonphysiological regulation of CAR-signaling and limits their accessibility due to logistical challenges, high costs and biosafety requirements. Random gene transfer modalities pose a risk of malignant transformation by insertional mutagenesis. Here, we propose a novel approach utilizing CRISPR-Cas gene editing to redirect T cells and natural killer (NK) cells with CARs. By transferring shorter, truncated CAR-transgenes lacking a main activation domain into the human CD3ζ (CD247) gene, functional CAR fusion-genes are generated that exploit the endogenous CD3ζ gene as the CAR's activation domain. Repurposing this T/NK-cell lineage gene facilitated physiological regulation of CAR expression and redirection of various immune cell types, including conventional T cells, TCRγ/δ T cells, regulatory T cells, and NK cells. In T cells, CD3ζ in-frame fusion eliminated TCR surface expression, reducing the risk of graft-versus-host disease in allogeneic off-the-shelf settings. CD3ζ-CD19-CAR-T cells exhibited comparable leukemia control to TCRα chain constant (TRAC)-replaced and lentivirus-transduced CAR-T cells in vivo. Tuning of CD3ζ-CAR-expression levels significantly improved the in vivo efficacy. Notably, CD3ζ gene editing enabled redirection of NK cells without impairing their canonical functions. Thus, CD3ζ gene editing is a promising platform for the development of allogeneic off-the-shelf cell therapies using redirected killer lymphocytes.
引用
- Kath J, Franke C, Drosdek V, et al. Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells. Blood. 2024. PMID: 38493479. doi:10.1182/blood.2023020973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。